Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
Division of Clinical Hypertension, Endocrinology and Metabolism, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8576, Japan.
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e3969-e3978. doi: 10.1210/clinem/dgab420.
Adrenocorticotropic hormone (ACTH) can contribute to aldosterone excess in primary aldosteronism (PA) via increased melanocortin type 2 receptor expression. Dynamic manipulation of the hypothalamic-pituitary-adrenal (HPA) axis could assist PA subtyping, but a direct comparison of dynamic tests is lacking.
To investigate plasma steroid differences between aldosterone-producing adenoma (APA) and bilateral PA (BPA) relative to ACTH variations.
We conducted comprehensive dynamic testing in 80 patients: 40 with APA and 40 with BPA. Peripheral plasma was collected from each patient at 6 time points: morning; midnight; after 1 mg dexamethasone suppression; and 15, 30, and 60 minutes after ACTH stimulation. We quantified 17 steroids by mass spectrometry in response to ACTH variations in all patients and compared their discriminative power between the 2 PA subtypes.
Patients with APA had higher morning and midnight concentrations of 18-hydroxycortisol, 18-oxocortisol, aldosterone, and 18-hydroxycorticosterone than those with BPA (P < 0.001 for all). In response to cosyntropin stimulation, the APA group had larger increments of aldosterone, 18-oxocortisol, 11-deoxycorticosterone, corticosterone, and 11-deoxycortisol (P < 0.05 for all). Following dexamethasone suppression, the APA group had larger decrements of aldosterone, 18-hydroxycortisol, and 18-oxocortisol (P < 0.05 for all), but their concentrations remained higher than in the BPA group (P < 0.01 for all). The highest discriminatory performance between the PA subtypes was achieved using steroids measured 15 minutes post-ACTH stimulation (area under receiver operating characteristic curve 0.957).
Steroid differences between APA and BPA are enhanced by dynamic HPA testing; such noninvasive tests could circumvent the need for adrenal vein sampling in a subset of patients with PA.
促肾上腺皮质激素(ACTH)可通过增加黑素皮质素 2 型受体的表达导致原发性醛固酮增多症(PA)中的醛固酮过多。对下丘脑-垂体-肾上腺(HPA)轴的动态操作可以辅助 PA 亚型分类,但缺乏对动态测试的直接比较。
研究相对于 ACTH 变化,醛固酮分泌腺瘤(APA)和双侧 PA(BPA)患者之间的血浆类固醇差异。
我们对 80 名患者进行了全面的动态测试:40 名 APA 患者和 40 名 BPA 患者。从每位患者的 6 个时间点采集外周血浆:早晨;午夜;1 mg 地塞米松抑制后;以及 ACTH 刺激后 15、30 和 60 分钟。我们通过质谱法定量了所有患者对 ACTH 变化的 17 种类固醇,并比较了它们在这两种 PA 亚型之间的鉴别能力。
与 BPA 患者相比,APA 患者的早晨和午夜 18-羟基皮质醇、18-氧皮质醇、醛固酮和 18-羟基皮质酮浓度更高(所有 P 值均<0.001)。在对促皮质素刺激的反应中,APA 组的醛固酮、18-氧皮质醇、11-脱氧皮质酮、皮质酮和 11-脱氧皮质醇的增加幅度更大(所有 P 值均<0.05)。在地塞米松抑制后,APA 组的醛固酮、18-羟基皮质醇和 18-氧皮质醇的下降幅度更大(所有 P 值均<0.05),但它们的浓度仍高于 BPA 组(所有 P 值均<0.01)。在 PA 亚型之间,使用 ACTH 刺激后 15 分钟测量的类固醇获得了最高的鉴别性能(接受者操作特征曲线下面积 0.957)。
通过动态 HPA 测试增强了 APA 和 BPA 之间的类固醇差异;这些非侵入性测试可以避免在一部分 PA 患者中进行肾上腺静脉取样。